{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:37:36Z","timestamp":1784039856753,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ad.2025.104583","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T19:08:19Z","timestamp":1767208099000},"page":"104583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of Oral Tetracyclines in Preventing Acneiform Rash in Patients With Non-small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3108-8821","authenticated-orcid":false,"given":"R.","family":"Sousa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vieira Granja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Magina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.104583_bib0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cac2.12505","article-title":"Management of locally advanced non-small cell lung cancer: state of the art and future directions","volume":"44","author":"Miao","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.ad.2025.104583_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103305","article-title":"Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis","volume":"160","author":"Zhao","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ad.2025.104583_bib0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2025.104583_bib0155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2025.104583_bib0160","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","article-title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2025.104583_bib0165","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2021.02.025","article-title":"Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: results from a randomized, open-label, phase 3 trial (ARCHER 1050)","volume":"154","author":"Cheng","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ad.2025.104583_bib0170","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3892\/ol.2022.13649","article-title":"Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: a systematic review and meta-analysis","volume":"25","author":"Obradovic","year":"2022","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ad.2025.104583_bib0175","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/ajco.13740","article-title":"Prevention and management of acneiform rash associated with EGFR inhibitor therapy: a systematic review and meta-analysis","volume":"18","author":"Gorji","year":"2022","journal-title":"Asia-Pac J Clin Oncol"},{"key":"10.1016\/j.ad.2025.104583_bib0180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-4632.2010.04791.x","article-title":"Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors","volume":"50","author":"Balagula","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.104583_bib0185","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ad.2025.104583_bib0190","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.drudis.2017.10.004","article-title":"Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors","volume":"23","author":"Singh","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ad.2025.104583_bib0195","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jjco\/hyv207","article-title":"Skin problems and EGFR-tyrosine kinase inhibitor","volume":"46","author":"Kozuki","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ad.2025.104583_bib0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdermsci.2013.05.009","article-title":"Recent advances in the epidermal growth factor receptor\/ligand system biology on skin homeostasis and keratinocyte stem cell regulation","volume":"72","author":"Nanba","year":"2013","journal-title":"J Dermatol Sci"},{"issue":"suppl 1","key":"10.1016\/j.ad.2025.104583_bib0205","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","article-title":"Overview of current systemic management of EGFR-mutant NSCLC","volume":"29","author":"Hsu","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ad.2025.104583_bib0210","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.104583_bib0215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ad.2025.104583_bib0220","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2021.02.025","article-title":"Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: results from a randomized, open-label, phase 3 trial (ARCHER 1050)","volume":"154","author":"Cheng","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ad.2025.104583_bib0225","doi-asserted-by":"crossref","first-page":"15117","DOI":"10.1002\/cam4.6184","article-title":"Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: a multicenter, phase II trial","volume":"12","author":"Iwasaku","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ad.2025.104583_bib0230","doi-asserted-by":"crossref","first-page":"252","DOI":"10.21037\/tlcr-20-649","article-title":"A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401)","volume":"10","author":"Okajima","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ad.2025.104583_bib0235","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.2147\/OTT.S145613","article-title":"Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer","volume":"10","author":"Ichiki","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ad.2025.104583_bib0240","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdw227","article-title":"A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer","volume":"27","author":"Lacouture","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ad.2025.104583_bib0245","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jaad.2016.01.019","article-title":"Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: a randomized, open-label trial","volume":"74","author":"Deplanque","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104583_bib0250","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.lungcan.2015.03.019","article-title":"Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients","volume":"88","author":"Arrieta","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ad.2025.104583_bib0255","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1200\/JCO.2015.62.3918","article-title":"Pan canadian rash trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancer","volume":"34","author":"Melosky","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2025.104583_bib0260","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ad.2025.104583_bib0265","first-page":"1691","article-title":"Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study","volume":"21","author":"Grande","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ad.2025.104583_bib0270","unstructured":"Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC; Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON). Unpublished results"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025008592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025008592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:34:02Z","timestamp":1777937642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025008592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0001731025008592"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.104583","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Oral Tetracyclines in Preventing Acneiform Rash in Patients With Non-small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.104583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of AEDV.","name":"copyright","label":"Copyright"}],"article-number":"104583"}}